here's the feature news in that article.
Biopharmaceutical firm AlphaRx says that data from preclinical trials of its inhaled drug Zysolin (tobramycin nanoparticles) demonstrate that it has superior efficacy in murine models of acute Pseudomonas aeruginosa pneumonia, compared with injectable forms of the anti-infective
Zysolin is intended for the adjunctive treatment of Pseudomonas aeruginosa pneumonia in intubated and mechanically-ventilated patients (VAP). It is being developed to replace injectable forms of the drug that currently dominate the market.
"P. aeruginosa is one of the most common and lethal pathogens responsible for ventilator-associated pneumonia in intubated patients, with directly attributable death rates reaching 40%. Reducing this mortality rate may be possible, if a more effective therapy for the treatment of Pseudomonas VAP can be developed," said Michael Weisspapir, CMS of AlphaRx.
"If approved, Zysolin(TM) could be a first-in-class cell-targeted nanomedicine which is designed to target intracellular pathogens that have proven to be very difficult to eradicate clinically," added by Dr. Weisspapir.
